Tower Research Capital (TRC)’s vTv Therapeutics VTVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,268
| Closed | -$50.7K | – | 5609 |
|
|
2025
Q4 | $50.7K | Buy |
+1,268
| New | +$35.3K | ﹤0.01% | 2403 |
|
|
2025
Q2 | – | Sell |
-394
| Closed | -$6.82K | – | 5596 |
|
|
2025
Q1 | $6.82K | Buy |
+394
| New | +$6.58K | ﹤0.01% | 4007 |
|
|
2024
Q4 | – | Sell |
-269
| Closed | -$3.65K | – | 6040 |
|
|
2024
Q3 | $3.65K | Buy |
+269
| New | +$4.46K | ﹤0.01% | 4804 |
|
|
2024
Q2 | – | Sell |
-535
| Closed | -$12.6K | – | 6036 |
|
|
2024
Q1 | $12.6K | Sell |
535
-535
| -50% | -$6.8K | ﹤0.01% | 3468 |
|
|
2023
Q4 | $12.3K | Buy |
+1,070
| New | +$15K | ﹤0.01% | 4051 |
|
|
2022
Q4 | – | Sell |
-114
| Closed | -$4K | – | 6424 |
|
|
2022
Q3 | $4K | Buy |
+114
| New | +$4.49K | ﹤0.01% | 5301 |
|
|
2022
Q2 | – | Sell |
-195
| Closed | -$6K | – | 6563 |
|
|
2022
Q1 | $6K | Buy |
+195
| New | +$5.84K | ﹤0.01% | 4939 |
|
|
2021
Q4 | – | Sell |
-1,021
| Closed | -$63K | – | 6610 |
|
|
2021
Q3 | $63K | Buy |
1,021
+50
| +5% | +$3.77K | ﹤0.01% | 2773 |
|
|
2021
Q2 | $89K | Buy |
971
+702
| +261% | +$71.1K | ﹤0.01% | 2525 |
|
|
2021
Q1 | $30K | Buy |
269
+136
| +102% | +$13.4K | ﹤0.01% | 3571 |
|
|
2020
Q4 | $10K | Sell |
133
-102
| -43% | -$7.82K | ﹤0.01% | 4327 |
|
|
2020
Q3 | $17K | Sell |
235
-24
| -9% | -$2.11K | ﹤0.01% | 3915 |
|
|
2020
Q2 | $23K | Buy |
+259
| New | +$25.6K | ﹤0.01% | 3608 |
|
|
2018
Q3 | – | Sell |
-21
| Closed | -$1K | – | 4290 |
|
|
2018
Q2 | $1K | Sell |
21
-124
| -86% | -$9.16K | ﹤0.01% | 3522 |
|
|
2018
Q1 | $24K | Buy |
145
+113
| +353% | +$27.7K | ﹤0.01% | 2083 |
|
|
2017
Q4 | $8K | Buy |
+32
| New | +$7.17K | ﹤0.01% | 2686 |
|
|
2017
Q3 | – | Sell |
-42
| Closed | -$8K | – | 4172 |
|
|
2017
Q2 | $8K | Buy |
42
+17
| +68% | +$3.54K | ﹤0.01% | 1746 |
|
|
2017
Q1 | $7K | Sell |
25
-28
| -53% | -$6.39K | ﹤0.01% | 2034 |
|
|
2016
Q4 | $10K | Buy |
+53
| New | +$12.2K | ﹤0.01% | 2673 |
|
|
2016
Q2 | – | Sell |
-54
| Closed | -$11K | – | 5037 |
|
|
2016
Q1 | $11K | Buy |
54
+28
| +108% | +$6.97K | ﹤0.01% | 1886 |
|
|
2015
Q4 | $7K | Sell |
26
-320
| -92% | -$89.8K | ﹤0.01% | 2626 |
|
|
2015
Q3 | $90K | Buy |
+346
| New | +$121K | 0.01% | 624 |
|
Other funds holding VTVT
SB
SL
BBA
TECP
VCM
VFT
Tower Research Capital (TRC)'s VTVT Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of vTv Therapeutics (VTVT) in Q1 2026, closing a stake of 1,268 shares — an estimated $50.7K sold.
Tower Research Capital (TRC) first reported a position in VTVT in Q3 2015 and held it in 22 quarters. The position peaked at $90K in Q3 2015. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining vTv Therapeutics position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,268 vTv Therapeutics shares in Q1 2026, an estimated $50.7K.
- Tower Research Capital (TRC) first reported a position in vTv Therapeutics in Q3 2015 and held it in 22 quarters.
- Tower Research Capital (TRC)'s vTv Therapeutics position peaked at $90K in Q3 2015.
- 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.